Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22681237 | 0.85 | GAA (0.32) | ALDH1A1GAA | |
| SCHEMBL24169552 | 0.85 | GAA (0.32) | ALDH1A1GAA | |
| SCHEMBL23793983 | 0.85 | GAA (0.32) | ALDH1A1GAA | |
| SCHEMBL24088686 | 0.85 | GAA (0.32) | ALDH1A1GAA | |
| SCHEMBL19890884 | 0.84 | MAPK1 (0.36) | MAPK1POLBHSD17B10CYP2C19PKM | |
| SCHEMBL21420082 | 0.82 | MAPK1 (0.35) | MAPK1POLBHSD17B10CYP2C19TSHR | |
| SCHEMBL21420081 | 0.82 | MAPK1 (0.35) | MAPK1POLBHSD17B10CYP2C19TSHR | |
| SCHEMBL21695112 | 0.81 | POLB (0.36) | MAPK1POLBHSD17B10CYP2C19PKM | |
| SCHEMBL19875674 | 0.80 | MAPK1 (0.35) | MAPK1POLBHSD17B10CYP2C19PKM | |
| SCHEMBL21643202 | 0.80 | MAPK1 (0.35) | MAPK1POLBHSD17B10CYP2C19PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654827-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654827-B2 | Therapeutic compounds | HAVCR2, MAVS, EIF2AK2 | MAPK1 3679/4885POLB 254/4885HSD17B10 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.